Drugs / ISLA101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06528457 | Sep 2024 → May 2025 | dengue disease | Island Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-15 | Island Pharmaceuticals | IRB approval received for ISLA101 Phase 2a clinical trial irmau.com ↗ |
| 2022-12-15 | Island Pharmaceuticals | ISLA101 drug product achieves stability milestone irmau.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISLA101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06528457 ↗ |
| Route | Oral | “ISLA101 capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).” NCT06528457 ↗ |